论文部分内容阅读
目的 :评价法玛新与丝裂霉素C膀胱灌注预防膀胱癌术后复发的疗效。方法 :将 5 8例膀胱癌患者分为两组 ,分别接受法玛新和丝裂霉素C治疗 ,随访 12～ 18个月。结果 :法玛新组 31例 ,复发 2例 ,复发率 6 .5 % ;丝裂霉素C组 2 7例 ,复发 9例 ,复发率 33.4 % ;两组相比差异有显著性意义 (P <0 .0 5 )。结论 :法玛新膀胱灌注预防膀胱癌术后复发疗效满意 ,优于丝裂霉素C。
Objective: To evaluate the efficacy of intravesical instillation of Famazine and mitomycin C in the prevention of postoperative recurrence of bladder cancer. Methods: Fifty-eight patients with bladder cancer were divided into two groups and received Famazin and Mitomycin C respectively. The patients were followed up for 12-18 months. Results: There were 31 cases in Fama new group, 2 cases relapsed, the recurrence rate was 6.5%. In mitomycin C group 27 cases, 9 cases relapsed, the recurrence rate was 33.4%. There was significant difference between the two groups (P <0 .0 5). Conclusion: Fama new bladder irrigation prevention of postoperative recurrence of bladder cancer curative effect is better than mitomycin C.